View Item 

Show simple item record

Nivolumab(N)-Avd Improves Progression-Free Survival Compared To Brentuximab Vedotin(Bv)-Avd In Advanced Stage (As) Classic Hodgkin Lymphoma (Hl): Results Of Swog S1826
dc.contributor.authorHerrera, A. F.
dc.contributor.authorLeBlanc, M.
dc.contributor.authorCastellino, S. M.
dc.contributor.authorLi, H.
dc.contributor.authorRutherford, S. C.
dc.contributor.authorEvens, A. M.
dc.contributor.authorDavison, K.
dc.contributor.authorPunnett, A.
dc.contributor.authorHodgson, D.
dc.contributor.authorParsons, S. K.
dc.contributor.authorAhmed, S.
dc.contributor.authorCasulo, C.
dc.contributor.authorBartlett, N. L.
dc.contributor.authorTuscano, J. M.
dc.contributor.authorMei, M. G.
dc.contributor.authorHess, B. T.
dc.contributor.authorJacobs, R.
dc.contributor.authorSaeed, H.
dc.contributor.authorTorka, P.
dc.contributor.authorHu, B.
dc.contributor.authorMoskowitz, C.
dc.contributor.authorKaur, S.
dc.contributor.authorGoyal, G.
dc.contributor.authorForlenza, C.
dc.contributor.authorDoan, A.
dc.contributor.authorLamble, A.
dc.contributor.authorKumar, P.
dc.contributor.authorChowdhury, S.
dc.contributor.authorBrinker, B.
dc.contributor.authorSharma, N.
dc.contributor.authorSingh, A.
dc.contributor.authorBlum, K.
dc.contributor.authorPerry, A. M.
dc.contributor.authorKovach, A.
dc.contributor.authorConstine, L. S.
dc.contributor.authorShields, L. Kostakoglu
dc.contributor.authorPrica, A.
dc.contributor.authorLittle, R. F.
dc.contributor.authorShipp, M. A.
dc.contributor.authorCrump, M.
dc.contributor.authorKahl, B.
dc.contributor.authorLeonard, J. P.
dc.contributor.authorSmith, S. M.
dc.contributor.authorSong, J. Y.
dc.contributor.authorKelly, K. M.
dc.contributor.authorFriedberg, J. W.
dc.date.accessioned2024-09-05T17:18:05Z
dc.date.available2024-09-05T17:18:05Z
dc.date.issued2023-06
dc.identifier.citationHerrera, A. F.; LeBlanc, M.; Castellino, S. M.; Li, H.; Rutherford, S. C.; Evens, A. M.; Davison, K.; Punnett, A.; Hodgson, D.; Parsons, S. K.; Ahmed, S.; Casulo, C.; Bartlett, N. L.; Tuscano, J. M.; Mei, M. G.; Hess, B. T.; Jacobs, R.; Saeed, H.; Torka, P.; Hu, B.; Moskowitz, C.; Kaur, S.; Goyal, G.; Forlenza, C.; Doan, A.; Lamble, A.; Kumar, P.; Chowdhury, S.; Brinker, B.; Sharma, N.; Singh, A.; Blum, K.; Perry, A. M.; Kovach, A.; Constine, L. S.; Shields, L. Kostakoglu; Prica, A.; Little, R. F.; Shipp, M. A.; Crump, M.; Kahl, B.; Leonard, J. P.; Smith, S. M.; Song, J. Y.; Kelly, K. M.; Friedberg, J. W. (2023). "Nivolumab(N)-Avd Improves Progression-Free Survival Compared To Brentuximab Vedotin(Bv)-Avd In Advanced Stage (As) Classic Hodgkin Lymphoma (Hl): Results Of Swog S1826." Hematological Oncology 41: 33-35.
dc.identifier.issn0278-0232
dc.identifier.issn1099-1069
dc.identifier.urihttps://hdl.handle.net/2027.42/194877
dc.publisherWiley Periodicals, Inc.
dc.titleNivolumab(N)-Avd Improves Progression-Free Survival Compared To Brentuximab Vedotin(Bv)-Avd In Advanced Stage (As) Classic Hodgkin Lymphoma (Hl): Results Of Swog S1826
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelNeurosciences
dc.subject.hlbsecondlevelObstetrics and Gynecology
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelOphthalmology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/194877/1/hon5_3163.pdf
dc.identifier.doi10.1002/hon.3163_5
dc.identifier.sourceHematological Oncology
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hon5_3163.pdf
Size:
183.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.